原发与继发性肌层浸润性膀胱癌的基因组差异及顺铂新辅助化疗疗效差异
研究比较245例原发与43例继发性肌层浸润性膀胱癌(MIBC)患者接受顺铂新辅助化疗(NAC)加根治性膀胱切除的结局,继发性MIBC病理缓解率更低且生存更差。基因组分析发现可能致病的ERCC2错义突变在原发MIBC中显著富集,提示其与顺铂敏感性相关。
要点
- 继发性MIBC接受顺铂NAC的病理缓解率低于原发MIBC(26% vs 45%)。
- 继发性MIBC接受NAC的肿瘤特异性生存劣于单纯膀胱切除。
- ERCC2错义突变在原发MIBC中富集,或解释两者化疗敏感性差异。
核心结论
- 继发性MIBC患者接受顺铂NAC的临床结局劣于原发MIBC,ERCC2突变在原发MIBC中富集并可能介导顺铂敏感性。
- 鉴于继发性MIBC缺乏顺铂NAC临床获益,可考虑 upfront 根治性膀胱切除或入组临床试验。
研究设计与样本
- 回顾性比较2001至2015年MSKCC的245例临床T2-4aN0M0原发MIBC与43例继发性MIBC接受NAC加根治性膀胱切除的 clinicopathologic 结局。
- 基因组差异在385例化疗前标本(全外显子或靶向外显子捕获测序)中评估,并在94例前瞻性靶向外显子测序的独立验证队列中确认。
主要发现
- 继发性MIBC的病理缓解率低于原发MIBC:单变量26% vs 45%,多变量OR=0.4(95%CI 0.18-0.84),p=0.02。
- 继发性MIBC的RFS、CSS和OS显著更差。
- 继发性MIBC接受NAC者CSS劣于单纯膀胱切除(p=0.002)。
- 可能致病的ERCC2错义突变在原发MIBC中更多:发现队列10.9%(36/330)vs 1.8%(1/55),p=0.04;验证队列15.7%(12/70)vs 0%(0/24),p=0.03。
关键数值与推荐
- 病理缓解率:继发性MIBC 26% vs 原发MIBC 45%(单变量);多变量OR=0.4(95%CI 0.18-0.84),p=0.02。
- ERCC2错义突变:发现队列原发10.9%(36/330)vs 继发1.8%(1/55),p=0.04;验证队列原发15.7%(12/70)vs 继发0%(0/24),p=0.03。
临床怎么用
- 对继发性MIBC应权衡顺铂NAC的获益,可考虑 upfront 根治性膀胱切除或临床试验入组。
- ERCC2突变状态有望作为顺铂敏感性生物标志物,但尚需前瞻性验证。
局限性
- 研究为回顾性设计,继发性MIBC样本量较小(43例)。
- 基因组分析为回顾性,结论仍需前瞻性验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Cisplatin-based neoadjuvant chemotherapy (NAC) followed by radical cystectomy (RC) is the standard of care for patients with muscle-invasive bladder cancer (MIBC). It is unknown whether this treatment strategy is appropriate for patients who progress to MIBC after treatment for prior noninvasive disease (secondary MIBC). OBJECTIVE: To determine whether clinical and genomic differences exist between primary and secondary MIBC treated with NAC and RC. DESIGN, SETTING, AND PARTICIPANTS: Clinicopathologic outcomes were compared between 245 patients with clinical T2-4aN0M0-stage primary MIBC and 43 with secondary MIBC treated with NAC and RC at Memorial Sloan Kettering Cancer Center (MSKCC) from 2001 to 2015. Genomic differences were assessed in a retrospective cohort of 385 prechemotherapy specimens sequenced by whole-exome or targeted exon capture by the Cancer Genome Atlas or at MSKCC. Findings were confirmed in an independent validation cohort of 94 MIBC patients undergoing prospective targeted exon sequencing at MSKCC. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Pathologic response rates, recurrence-free survival (RFS), bladder cancer-specific survival (CSS), and overall survival (OS) were measured. Differences in somatic genomic alteration rates were compared using Fisher's exact test and the Benjamini-Hochberg false discovery rate method. RESULTS AND LIMITATIONS: Patients with secondary MIBC had lower pathologic response rates following NAC than those with primary MIBC (univariable: 26% vs 45%, multivariable: odds ratio=0.4 [95% confidence interval=0.18-0.84] p=0.02) and significantly worse RFS, CSS, and OS. Patients with secondary MIBC treated with NAC had worse CSS compared with cystectomy alone (p=0.002). In a separate genomic analysis, we detected significantly more likely deleterious somatic ERCC2 missense mutations in primary MIBC tumors in both the discovery (10.9% [36/330] vs 1.8% [1/55], p=0.04) and the validation (15.7% [12/70] vs 0% [0/24], p=0.03) cohort. CONCLUSIONS: Patients with secondary MIBC treated with NAC had worse clinical outcomes than similarly treated patients with primary MIBC. ERCC2 mutations predicted to result in increased cisplatin sensitivity were enriched in primary versus secondary MIBC. Prospective validation is still needed, but given the lack of clinical benefit with cisplatin-based NAC in patients with secondary MIBC, upfront RC or enrollment in clinical trials should be considered. PATIENT SUMMARY: A retrospective cohort study of patients with "primary" and "secondary" muscle-invasive bladder cancer (MIBC) treated with chemotherapy before surgical removal of the bladder identified lower response rates and shorter survival in patients with secondary MIBC. Tumor genetic sequencing of separate discovery and validation cohorts revealed that chemotherapy-sensitizing DNA damage repair gene mutations occur predominantly in primary MIBC tumors and may underlie the greater sensitivity of primary MIBC to chemotherapy. Prospective validation is still needed, but patients with secondary MIBC may derive greater benefit from upfront surgery or enrollment in clinical trials rather than from standard chemotherapy.
引用
- Pietzak EJ, Zabor EC, Bagrodia A, et al. Genomic Differences Between "Primary" and "Secondary" Muscle-invasive Bladder Cancer as a Basis for Disparate Outcomes to Cisplatin-based Neoadjuvant Chemotherapy. Eur Urol. 2018. PMID: 30290956. doi:10.1016/j.eururo.2018.09.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。